Overview of the immune biology of allogeneic hematopoietic stem cell transplantation - Immune Biology of Allogeneic Hematopoietic Stem Cell Transplantation - page 15

[51] Hubbard VM, Eng JM, Ramirez-Montagut T, Tjoe KH, Muriglan SJ, Kochman AA, et al.
Absence of inducible costimulator on alloreactive T cells reduces graft versus host
disease and induces Th2 deviation. Blood 2005;106(9):3285-92.
[52] Taylor PA, Panoskaltsis-Mortari A, Freeman GJ, Sharpe AH, Noelle RJ, Rudensky AY,
et al. Targeting of inducible costimulator (ICOS) expressed on alloreactive T cells down-
regulates graft-versus-host disease (GVHD) and facilitates engraftment of allogeneic
bone marrow (BM). Blood 2005;105(8):3372-80.
[53] Blazar BR, Carreno BM, Panoskaltsis-Mortari A, Carter L, Iwai Y, Yagita H, et al. Block-
ade of programmed death-1 engagement accelerates graft-versus-host disease lethality
by an IFN-gamma-dependent mechanism. J Immunol 2003;171(3):1272-7.
[54] Jasperson LK, Bucher C, Panoskaltsis-Mortari A, Taylor PA, Mellor AL, Munn DH, et al.
Indoleamine 2,3-dioxygenase is a critical regulator of acute graft-versus-host disease
lethality. Blood 2008;111(6):3257-65.
[55] Reddy P, Sun Y, Toubai T, Duran-Struuck R, Clouthier SG, Weisiger E, et al. Histone
deacetylase inhibition modulates indoleamine 2,3-dioxygenase-dependent DC
functions and regulates experimental graft-versus-host disease in mice. J Clin Invest
2008;118(7):2562-73.
[56] Steckel NK, Kuhn U, Beelen DW, Elmaagacli AH. Indoleamine 2,3-dioxygenase
expression in patients with acute graft-versus-host disease after allogeneic stem cell
transplantation and in pregnant women: association with the induction of allogeneic
immune tolerance? Scand J Immunol 2003;57(2):185-91.
[57] Davies JK, Gribben JG, Brennan LL, Yuk D, Nadler LM, Guinan EC. Outcome of al-
loanergized haploidentical bone marrow transplantation after ex vivo costimulatory
blockade: results of 2 phase 1 studies. Blood 2008;112(6):2232-41.
[58] Guinan EC, Boussiotis VA, Neuberg D, Brennan LL, Hirano N, Nadler LM, et al.
Transplantation of anergic histoincompatible bone marrow allografts. N Engl J Med
1999;340(22):1704-14.
[59] Andre-Schmutz I, Le Deist F, Hacein-Bey-Abina S, Vitetta E, Schindler J, Chedeville G, et al.
Immune reconstitution without graft-versus-host disease after haemopoietic stem-cell
transplantation: a phase 1/2 study. Lancet 2002;360(9327):130-7.
[60] Ingelfinger JR, Schwartz RS. Immunosuppression - the promise of specificity. N Engl J
Med 2005;353(8):836-9.
[61] Beilhack A, Schulz S, Baker J, Beilhack GF, Wieland CB, Herman EI, et al. In vivo analy-
ses of early events in acute graft-versus-host disease reveal sequential infiltration of
T-cell subsets. Blood 2005;106(3):1113-22.
[62] Anderson BE, McNiff J, Yan J, Doyle H, Mamula M, Shlomchik MJ, et al. Memory CD4 + T
cells do not induce graft-versus-host disease. J Clin Invest 2003;112(1):101-8.
[63] Anderson BE, McNiff JM, Matte C, Athanasiadis I, Shlomchik WD, Shlomchik MJ.
Recipient CD4 + T cells that survive irradiation regulate chronic graft-versus-host dis-
ease. Blood 2004;104(5):1565-73.
[64] Ermann J, Hoffmann P, Edinger M, Dutt S, Blankenberg FG, Higgins JP, et al. Only the
CD62L + subpopulation of CD4 + CD25 + regulatory T cells protects from lethal acute
GVHD. Blood 2005;105(5):2220-6.
[65] Taylor PA, Noelle RJ, Blazar BR. CD4( + )CD25( + ) immune regulatory cells are required
for induction of tolerance to alloantigen via costimulatory blockade. J Exp Med
2001;193(11):1311-8.
[66] Cohen JL, Trenado A, Vasey D, Klatzmann D, Salomon BL. CD4( + )CD25( + ) im-
munoregulatory T cells: new therapeutics for graft-versus-host disease. J Exp Med
2002;196(3):401-6.
[67] Edinger M, Hoffmann P, Ermann J, Drago K, Fathman CG, Strober S, et al. CD4 + CD25 +
regulatory T cells preserve graft-versus-tumor activity while inhibiting graft-versus-
host disease after bone marrow transplantation. Nat Med 2003;9(9):1144-50.
[68] Hoffmann P, Ermann J, Edinger M, Fathman CG, Strober S. Donor-type CD4( + )CD25( + )
regulatory T cells suppress lethal acute graft-versus-host disease after allogeneic bone
marrow transplantation. J Exp Med 2002;196(3):389-99.
[69] SJ, Ramirez-Montagut T, Alpdogan O, Van Huystee TW, Eng JM, Hubbard VM, et al.
GITR activation induces an opposite effect on alloreactive CD4( + ) and CD8( + ) T cells in
graft-versus-host disease. J Exp Med 2004;200(2):149-57.
[70] Zeiser R, Leveson-Gower DB, Zambricki EA, Kambham N, Beilhack A, Loh J, et al.
Differential impact of mammalian target of rapamycin inhibition on CD4 + CD25 + Foxp3 +
regulatory T cells compared with conventional CD4 + T cells. Blood 2008;111(1):453-62.
[71] Liu W, Putnam AL, Xu-Yu Z, Szot GL, Lee MR, Zhu S, et al. CD127 expression inversely
correlates with FoxP3 and suppressive function of human CD4 + T reg cells. J Exp Med
2006;203(7):1701-11.

15